Another study found that GLP-1 agonists are associated with a lower risk of major adverse kidney events and death from cardiovascular causes in people with type 2 diabetes and chronic kidney disease
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, Phase 2 trial
Conduct Thorough Patient Assessments Medical History : Check for pre-existing conditions (e.g., kidney issues, hormonal imbalances, or allergies)
The vitamins C and E can also perform the same function alongside other purported benefits
The frequency of these injections can vary from daily to monthly, depending on how severe the deficiency is and how well the patient responds
In this ~2-minute video, Omada summarizes findings of our July 2025 clinical white paper: GLP-1 Persistence: A Key Component of Weight Loss